✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Concord Drugs Ltd.

CONCORD

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹98 Cr.
P/E
169.54

Concord Drugs Ltd.

  • Concord Drugs
  • Mercury Laboratories
  • Curis Lifesciences

FAQs on Concord Drugs Ltd. Shareprice

Concord Drugs has given better returns compared to its competitors.
Concord Drugs has grown at ~92.84% over the last 1yrs while peers have grown at a median rate of -43.0%

Yes, Concord Drugs is expensive.
Latest PE of Concord Drugs is 172, while 3 year average PE is 36.55.
Also latest EV/EBITDA of Concord Drugs is 25.41 while 3yr average is 11.75.

View FAQ's On Business

Growth Table

  • Concord Drugs Ltd.
  • Mercury Laboratories
  • Curis Lifesciences

Balance Sheet

  • Concord Drugs Ltd.
  • Mercury Laboratories
  • Curis Lifesciences

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Concord Drugs Ltd.
  • Mercury Laboratories
  • Curis Lifesciences

Cash Flow

  • Concord Drugs Ltd.
  • Mercury Laboratories
  • Curis Lifesciences

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Concord Drugs Ltd.
  • Mercury Laboratories
  • Curis Lifesciences

Quarterly Results

  • Concord Drugs Ltd.
  • Mercury Laboratories
  • Curis Lifesciences

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Concord Drugs Ltd. Financials

Balance sheet of Concord Drugs is strong.
But short term working capital might become an issue for this company.

The net debt of Concord Drugs is decreasing.
Latest net debt of Concord Drugs is ₹16.73 Crs as of Sep-25.
This is less than Mar-25 when it was ₹18.91 Crs.

The profit is oscillating.
The profit of Concord Drugs is ₹0.57 Crs for TTM, ₹0.34 Crs for Mar 2025 and ₹0.47 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Concord Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech